Nestlé Health Science Licenses Rights for LT-02 as Ulcerative Colitis Therapy

Nestlé Health Science Licenses Rights for LT-02 as Ulcerative Colitis Therapy
Nestlé Health Science recently announced that it has entered into a license partnership with Lipid Therapeutics, a biopharmaceutical company focused on the development and commercialization of phospholipids, for global exclusive rights (except in Australia and Europe) over Lipid Therapeutics’ LT-02 agent (phosphatidylcholine), a novel treatment able to improve the mucosal barrier function in patients with

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *